Anthropic CEO Dario Amodei believes cancer, Alzheimer's disease, heart disease and mental illness could become “relics of the past” in less than a decade, thanks to artificial intelligence (AI).The AI company has kicked off the roadshow for its US initial public offering (IPO), seeking to raise up to $64.4 billion at a valuation of around $1 trillion. The listing could mark the first public offering by a frontier AI lab.In the company's IPO roadshow video, Amodei spoke about AI's potential to transform human health, describing a future in which diseases that have long challenged medicine could be overcome.“We can create an age of miracles where humanity is able to solve problems that have eluded us for millennia,” he said.Amodei also addressed the risks associated with AI and invited investors to join the company's next phase of growth.Anthropic CEO Has Long Predicted AI Could Transform HealthcareThis is not the first time Amodei has spoken about AI's potential to transform healthcare. In a post on X, he wrote: “I think it will actually be possible to cure most human disease in ~5-10 years.”In two of his essays, Amodei discussed how advanced AI could accelerate biological and medical research, potentially compressing 50–100 years of scientific progress into five to 10 years.His predictions have covered several major health conditions, including:CancerAlzheimer's diseaseGenetic diseasesHeart disease, diabetes and obesitySchizophreniaMajor depressionHe has also discussed the possibility of AI helping humans live significantly longer.Anthropic's Expanding Healthcare InitiativesIn September, Anthropic partnered with medical knowledge platform OpenEvidence to provide AI-powered clinical decision support to healthcare providers in dozens of low- and middle-income countries. OpenEvidence uses peer-reviewed research and treatment guidelines to answer doctors' clinical questions, with the initiative expected to reach about 100 countries, including Uganda, Angola, Sudan, Haiti and Mongolia.Anthropic has also announced a Claude-led discovery of a molecular machine that researchers suspect could represent a new gene-editing mechanism, highlighting AI's potential to accelerate biological research.What Are The Ethical Risks Of Using AI In Healthcare?Major technology companies, including Google, are increasingly expanding their presence in healthcare through AI-powered tools and services. However, the growing use of AI in medicine also raises questions about patient safety, privacy and accountability.The World Health Organization (WHO) has called for stronger ethical oversight of AI-related health research.In a recent report, WHO warned that rapid advances in AI are creating challenges around privacy, bias, fairness, transparency and accountability. It said existing research ethics systems may need additional expertise to assess risks associated with AI and large datasets.Dr Rajeev Jayadevan, former president of IMA Cochin and convener of the Research Cell, Kerala, told HealthandMe that AI-driven research, particularly when it involves large datasets crossing national borders, may require ethics committees to include experts in computer science, data ethics and bioinformatics.“Ethics Committees by themselves will need to be upgraded to incorporate computer scientists, data ethicists, and bioinformaticians.”WHO also said oversight should extend beyond ethics committees to researchers, funders, scientific journals, data governance bodies, professional societies and regulators.